UK Health Tech – Innovation Showcase

Introduction Manchester based SME, established by management buyout in November 2013 VC Funding £1.2 M loan notes plus £500 K cash Now a leading molecular diagnostics manufacturer and developer with proprietary technology and knowhow Suite of innovative in vitro diagnostic CE marked products Global market leading products in CFTR and Trisomy Products manufactured within an ISO accredited quality system to ensure optimal performance in the customer’s own laboratory Committed to providing new innovative diagnostic solutions through global collaborations In 2018 we are a company of 33 people exporting to approx. 50 markets, debts free, with revenues of circa £3.5 M and EBITDA of £1.2 M

Future Plans CDx Growth Vision \ Product Pipeline Pharmaceutical Partners Genetics Customers Diagnostic Partners Diagnostics Bioinformatics Solutions Companion Diagnostics PCR CE Technology Bioinformatics NGS Technology Product Pipeline Product Development Products CRO Partners CDx Growth Vision To become a global leading provider of Companion diagnostics in order to enable a personalised medicine approach for patients, whilst reduce cost burden to international healthcare systems. Direct expansion of Manchester Team Partnering Acquisition

Our market Current products reaching market saturation Traditional genetic diagnostics market is changing Focus from stand alone diagnostics is moving to personalised healthcare and companion diagnostics As an industry our innovations must support market needs Market driven by stagnated resources and an aging population with increasing expectations for a better standard of care Elucigene are committed to bring to market CDx products that increase standards of patient care and better utilise stretched resources Our innovations will bring us closer to our colleagues in pharmaceuticals Increasing payer expectation that drugs will come to market with a CDx if possible and appropriate Need to innovate our business model as well as our products For most SMEs partnering will be a key consideration for sucess

Oncology Oncology Rheumatology 5-FU is a toxic component of 2 M chemotherapy regimes each year Used in numerous cancer treatments – component of circa. 60 drugs on the market Defective DYPD enzyme activity results in 10 to 15 % adverse reactions and 1 % lethality Currently patient roulette is standard practice Genetic susceptibility screening is now possible, and 2018 sees guidance in place No CE IVD on the market to perform such screening Elucigene DYDP launches Spring 2019 Enables susceptibility screening in 4 hours at low cost – Circa £35.00 per test Susceptible individuals are placed on reduced or alternative therapy

Rheumatology Oncology Rheumatology Rituximab (MabThera, Rocej) – Monoclonal used in combination with methotrexate in the treatment of patients with Rheumatoid Arthritis Directed against B cells called CD-20 involved in the inflammatory process 2nd line treatment of patients non-responsive to disease-modifying antirheumatic drugs (DMARDs) such as anti-TNF drugs such as (Adalimumab, Etanercept, Infliximab) Not all patients will respond to Rituximab, resulting in 6 months prolonged inadequate treatment at the cost of £3500 plus to the NHS (Higher in other markets) Elucigene £700 K Eurostars Collaboration with TubaScan and ClinicaGenome to produce a predictive genetic screening tool for patients to inform likely response Rituximab Patients characterised by a profile of 8 mRNA SNPs Patients likely to be unresponsive are offered alternative therapy approaches such as Abatacept

Innovation Innovation is not always technology led Elucigene utilise existing technologies to transform patient pathways Partnering is key to success Diagnostics Manufacturers Funding Contract Research and Clinical Trial Organisations Academic Institutes Pharmaceuticals Health Care Providers (NHS)